The abstract is read at the publisher; the summary is JClub's.
In a clinical trial in up to 141 adults with major depressive disorder, a Dial-In multimethod ambulatory study will track how 25 mg psilocybin-linked daily-life changes relate to later symptom and adverse-effect outcomes over eight weeks.
- Why it matters: Depression responses to psilocybin vary, including limited improvement and adverse effects, yet prior research uses discrete assessments that miss how changes unfold in everyday life.
- What they did: Participants complete 14 days of ecological momentary assessment and voice diaries before and after dosing, plus passive audio sampling with the Electronically Activated Recorder for three four-day periods, while outcomes are measured through eight weeks post-dose.
- The result: Analyses will test whether daily affective sudden gains/losses, social support, interpersonal conflict, conversational focus, reflection, and rigidity predict differential clinical outcomes and whether these factors moderate links between challenging dosing experiences and those outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.